Applications published 26 September 2007

Compsn and method for treating hyperpigmented skin
Lipo Chemicals 1835884*

Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of a GNRH
Durect Corp 1835885*

Orally disintegrating pharmaceutical compsns with sensory cue agents
Warner-Lambert 1835886*

Mucoadhesive pharmaceutical compsns comprising chemoattractants
Universite de LiEge 1835887*

Cholanic acid-chitosan complex forming self-aggregates and preparation method thereof
Korea Institute of Science & Technology 1835888*

Nanoparticulate tacrolimus formulations
Elan Pharma International 1835889*

Nanoparticulate candesartan formulations
Elan Pharma International 1835890*

Solid pharmaceutical compsns
Novartis-Pharma 1835891*

Chewable oral compsns containing an anti-microbial agent and methods of formulating the compsns to have acceptable germ kill properties and taste
Cadbury Adams 1835892*

Pharmaceutical compsn containing coated, floating particles
Jagotec 1835893*

Solid lipidic particles as pharmaceutically acceptable fillers or carriers for inhalation
Universite Libre de Bruxelles 1835894*

Use of certain phenyl-naphthyl compounds that do not have significant affinity to ER alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis
Aventis Pharmaceuticals 1835895*

Use of certain phenyl-naphthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (MS)
Aventis Pharmaceuticals 1835896*

Oxygen-impervious packaging with optional oxygen scavenger, stabilised thyroid hormone compsns and methods for storing hormone pharmaceutical compsns
King Pharmaceuticals Research & Development 1835897*

Methods for modulating tumour growth and metastasis
Oxigene 1835898*

Treatment of HCV disorders
Novartis 1835899*

Sulphasalazine analogues as NF-KB inhibitors
University of Southampton 1835900*

Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof
Reliant Pharmaceuticals 1835901*

Complex formulation of 3-hydroxy-3-methyl glutaryl CoA reductase inhibitor and antihypertensive agent, and process for preparing same
Hanmi Pharm 1835903*

Compsn for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising vitamin C derivatives
Trichogene 1835904*

Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis
Aventis Pharmaceuticals 1835905*

Injectable or orally deliverable formulations of azetidine derivatives
Aventis Pharma 1835906*

Medicaments for the treatment or prevention of fibrotic diseases
Boehringer Ingelheim International 1835907*

Indole derivatives with antitumour activity
Cell Therapeutics 1835908*

Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
Novartis 1835909*

Methods of using [3.2.0] heterocyclic compounds and analogues thereof
Nereus Pharmaceuticals 1835910*

Therapeutic compsns for intranasal administration of ketorolac
Roxro Pharma 1835911*

Substituted benzimidazoles for treatment of histomoniasis
Bayer HealthCare 1835912*

Ibudilast for treating neuropathic pain and associated syndromes
Avigen 1835913*

Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders
Minster Research 1835914*

Immune response modifier formulations and methods
Coley Pharmaceutical 1835915*

Compounds useful in the treatment of HIV
Medivir 1835916*

Agents containing folic acid, vitamin B6 and vitamin B12, and the use thereof
Synavit 1835917*

Inhibitors of checkpoint kinases
Merck 1835918*

Dry eye treatment
Ocular Research of Boston 1835919*

Drugs for the treatment and/or prophylaxis of gastroparesis symptom
Chugai Seiyaku KK 1835920*

9A-carbamoyl-y-aminopropyl- and 9A-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
GlaxoSmithKline 1835921*

Combination treatment for multiple sclerosis
Laboratoires Serono 1835922*

Regimen for intra-articular viscosupplementation
Genzyme 1835923*

Treatment of parkinson's disease and related disorders using post-partum derived cells
Ethicon 1835924*

Method of reducing oral tissue inflammation using magnolia extract
Colgate-Palmolive 1835925*

Plasmin-inhibitory therapies
Dyax 1835926*

Modified beta thymosin peptides
Regenerx Biopharmaceuticals; Universitaet Erlangen-Nuerenberg 1835927*

MAS related G protein coupled receptors as drug targets
Rheoscience 1835928*

Anti-KIR combination treatments and methods
Novo-Nordisk; Innate Pharma 1835929*

Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
Fonterra 1835930*

Alpha thymosin peptides as cancer vaccine adjuvants
Sciclone Pharmaceuticals 1835931*

Methods to elicit, enhance and sustain immune responses against MHC class 1-restricted epitopes, for prophylactic or therapeutic purposes
Mannkind 1835932*

HSP60, HSP60 peptides and T call vaccine for immunomodulation
Yeda Research and Development Company 1835933*

Enzyme modulators and treatments
Deciphera Pharmaceuticals 1835934*

Compsns and methods for enhanced dendritic cell maturation and function
The Rockefeller University 1835935*

Compsns and methods for regulating apoptosis
Yeda Research and Development 1835936*

Compsns and methods for treating viral infection
Novo Nordisk; Innate Pharma 1835937*

Polymer-Von Willebrand factor-conjugates
Baxter International; Baxter Healthcare 1835938*

Meningococcal conjugate vaccination
Novartis Vaccines and Diagnostics 1835939*

Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
Forest Laboratories 1836153*

Polymorphs of memantine hydrochloride
Teva Pharmaceutical Fine Chemicals 1836154*

Processes for the preparation of aminoethoxybenzyl alcohols
Wyeth 1836155*

Substantially pure tolterodine tartrate and process for preparing thereof
Teva Gyrogyszergyar Resvenytarsasag 1836156*

Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
Teva Pharmaceutical Fine Chemicals 1836157*

Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation
Sanofi-Aventis Deutschland 1836158*

Peptidic compounds
University of Wollongong 1836159*

Compounds for treating metabolic syndrome
CTG Pharma 1836160*

Methods and compsns for treating amyloid-related diseases
Neurochem (International) 1836161*

Antibacterial agents
Idexx Laboratories 1836162*

Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
Novartis 1836163*

11C-labeled benzyl-lactam compounds and their use as imaging agents
Pfizer Products 1836164*

Dipyrrole compounds, compsns and methods for treating cancer or viral diseases
Germin X biotechnologies 1836165*

Glucocorticoid mimetics, methods of making them, pharmaceutical compsns, and uses thereof
Boehringer Ingelheim Pharmaceuticals 1836166*

Method to prepare bis(halophthalalimides)
General Electric 1836167*

Benzoyl-tetrahydropyridine as GLYT-1 inhibitors
F Hoffmann-La Roche 1836168*

Compsns and methods of treating cell proliferation disorders
Kinex Pharmaceuticals 1836169*

N-((2Z)-2-((4-hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulphonamide crystalline form 2
Abbott Laboratories 1836170*

5-HT7 receptor antagonists
Laboratoires del Dr Esteve 1836172*

Anti-inflammatory medicaments
Deciphera Pharmaceuticals 1836173*

Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
Amgen 1836174*

Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
Mallinckrodt 1836175*

Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
Bristol-Myers Squibb 1836176*

Vitamin D receptor modulators
Eli Lilly 1836177*

Sulphanyl substituted phenyl methanones as glycine transporter 1 (GLYT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
F Hoffmann-La Roche 1836178*

Piperazinyl and piperidinyl ureas as modulators of fatty acid hydrolase
Janssen Pharmaceutica 1836179*

Sulphonyl pyrrolidines, method for producing the same and their use as drugs
Sanofi-Aventis 1836180*

Methods and devices for the continuous processing of renewable raw materials
Biotech Progress 1836181*

Heterocyclylbiphenyl derivatives as protein tyrosine phosphatase inhibitors
The Institutes for Pharmaceutical Discovery 1836182*

Spiro derivatives as lipoxygenase inhibitors
Galileo Pharmaceuticals 1836183*

Improved process for he kumusa coupling reaction
Honeywell International 1836184*

Method for purifying (1S)-3-methylamino-1-(2-thienyl)-1-propanol
BASF 1836185*

Process for the isomerisation of 2-halothiophene to-3-halothiophene
Honeywell International 1836186*

1H-indole-3-carboxylic acid derivatives and their use as PPAR agonists
Merck Patent 1836187*

Pyrazole derivatives that modulate the activity of CDK, GSK and aurora kinases
Astex Therapeutics 1836188*

Novel pyridine compounds
AstraZeneca 1836189*

Preparation of pharmaceutical salts of piperazine compounds
Schering 1836190*

Pyrazolylamino substituted quinazoles for the treatment of cancer
AstraZeneca 1836191*

Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
Universita" Degli Studi di Siena 1836192*

Preparation of crude candersartan cilexetil
Teva Pharmaceutical Industries 1836195*

Tricyclic delta-opioid modulators
Janssen Pharmaceutica 1836196*

Selective muscle relaxant and pharmaceutical compsns
Universite Federal, do Rio de Janeiro 1836197*

Substituted pyrrolidinones having an antithrombitic effect, the production thereof and their use as medicaments
Boehringer Ingelheim International 1836198*

Thiazole and isothiazole derivatives that modulate the activity of CDK, GSK and Aurora kinases
Astex Therapeutics 1836199*

Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
Abbott Laboratories 1836200*

Pyrrolidine inhibitors of IAP
Genentech 1836201*

Aminophenyl derivatives as selective androgen receptor modulators
Acadia Pharmaceuticals 1836202*

Heteroaryl substituted quinolin-4-ylamine analogues
Neurogen Corp 1836203*

Radioactive metal complexes based on bispidine and derivatives thereof
Universitaet Heidelberg; Forschungszentrum Dresden 1836204*

Pyrazolo[1,5-A]pyrimidine adenosine A2a receptor antagonists
Schering 1836205*

Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
Bristol-Myers Squibb 1836206*

Triazolophthalazines as PDE2-inhibitors
Nycomed 1836207*

Amino-imidazolones for the inhibition of B-secretase
Wyeth 1836208*

Crystalline forms of 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic acid as inhibitors of CD18 integrins, ICMS and/or the LFA-1:ICAM interaction for the treatment of inflammation and immune diseases
Bristol-Myers Squibb 1836209*

Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethyliden]bisphosphonic acid and hemi-pentahydrate monosodium salt thereof
Zaklady Farmaceutyczne “Polpharma”; Polytechnika Gdanska 1836210*

Macrolides
Pfizer Products 1836211*

Macrolide compounds containing biotin and photoaffinity group for macrolide target identification
GlaxoSmithKline 1836212*

Compsns and methods for nucleic acid analysis of sequences with insertions or deletions
Autogenomics 1836213*

Compsns, methods and kits for engaging protein expression, solubility and isolation
Lifesensors 1836214*

Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions
Glaxo 1836215*